PRAGUE, Czech Republic, June 15, 2020 / B3C newswire / -- SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.
Poster presentation details
| Poster title: | SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent mannerSO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner |
| Abstract: | 6686 / 2 |
| Session: | Session PO.IM02.20 - Immunomodulatory Agents and Interventions 3 |
| Date/Time: | Monday, June 22, 2020, 9:00 a.m. – 6:00 p.m. EDT |
A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.
Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the Phase 1 clinical trial.
About SOTIO
SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
SOTIO is a registered trademark of SOTIO a.s. in selected countries.
Contacts
Company contact
Richard Kapsa
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact
Kirsten Frazer, Ph.D.
LifeSci Communications
T: +1 646-863-0222
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Drug Evaluation, Preclinical; Medical Oncology; IL15 protein, human; Interleukin-15; CD8-Positive T-Lymphocytes;
Published by B3C newswire and shared through Newronic®